209173-80-8

Usage

Uses

Used in Pharmaceutical Industry:
L-phenylalanine is used as a precursor in the synthesis of various pharmaceutical compounds, including neurotransmitters and other essential molecules. Its role in the production of dopamine, norepinephrine, and epinephrine makes it a valuable component in the development of medications targeting neurological and psychological disorders.
Used in Dietary Supplements:
L-phenylalanine is used as a dietary supplement to support the synthesis of proteins and neurotransmitters in the body. It can help improve cognitive function, mood, and overall well-being. Additionally, it is used in the treatment of phenylketonuria, a genetic disorder that requires a controlled intake of phenylalanine.
Used in Food and Beverage Industry:
L-phenylalanine is used as a flavor enhancer in the food and beverage industry. It is a component of aspartame, a low-calorie sweetener, and is also used to improve the taste and texture of certain food products.
Used in Cosmetics Industry:
L-phenylalanine is used in the cosmetics industry for its role in the synthesis of melanin, the pigment responsible for skin color. It can be used in skin lightening products to regulate melanin production and promote an even skin tone.
Used in Research and Development:
L-phenylalanine is utilized in research and development for its involvement in various biological processes and its potential applications in the treatment of medical conditions. It serves as a valuable tool for studying the mechanisms of protein synthesis, neurotransmission, and other physiological functions.

Upstream product

• 186393-18-0 ((S)-1-benzyl-2-cyano-2-hydroxy-ethyl)-carbamic acid tert-butyl ester 
• 191849-93-1 3(S)-(N-tert-butoxycarbonylamino)-2(R,S)-hydroxy-4-phenylbutyric acid 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 194086-30-1 ethyl (S)-(1-benzyl-3,3-dichloro-2-oxopropyl)carbamate 
• 67-56-1 methanol 
• 74-90-8 hydrogen cyanide 
• 72155-45-4 Boc-L-phenylalaninal 
• 3182-95-4 L-Phenylalaninol 
• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 87694-53-9 Boc-Phe-OH N,O-dimethyl hydroxamate 
• 66605-57-0 (S)-N-tert-butoxycarbonyl-2-amino-3-phenylpropanol 
• 143-33-9 sodium cyanide 
• 301544-38-7 tert-butyl ((2S)-4-(tert-butylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl)carbamate 
• 211676-28-7 1-(S)-cyano-2(S)-(N-tert-butoxycarbonylamino)-3-phenylpropyl benzoate 

Downstream Products

• 191849-93-1 3(S)-(N-tert-butoxycarbonylamino)-2(R,S)-hydroxy-4-phenylbutyric acid 
• 316830-82-7 [(S)-1-((S)-1-Benzyl-2-hydroxy-2-phenethylcarbamoyl-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid benzyl ester 
• 854585-36-7 3-amino-2-hydroxy-4-phenyl-N-propyl-butyramide 

Relevant academic research and scientific papers

COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER

The present invention provides a means for treating and/or preventing peripheral nerve disorder by facilitating regeneration of peripheral nerves. Specifically, the present invention provides a composition for treating and/or preventing peripheral nerve d

Lissencephaly therapeutic agent

An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wher

LISSENCEPHALY THERAPEUTIC AGENT

An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wher

Exploration of orally available calpain inhibitors: Peptidyl α-ketoamides containing an amphiphile at P3 site

A novel series of dipeptidyl α-ketoamide derivatives with amphiphile was designed and synthesized as water-soluble calpain inhibitors. The introduction of amphiphiles at the P3 site increased water solubility without loss of membrane permeability and prov

ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF

The present invention provides a compound represented by the formula (I): (INSERT CHEMICAL FORMULA) (wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group; R2 is a lower alkyl opti

Design, Synthesis, Molecular Modeling Studies, and Calpain Inhibitory Activity of Novel α-Ketoamides Incorporating Polar Residues at the P 1′-Position

A series of novel α-ketoamides incorporating stereoisomeric residues with different electronic properties at the P1′-position were synthesized to study the electronic requirements for inhibitor binding to the S1′-subsite of calpain I

Significance of hydrogen bonding at the S1′ subsite of calpain I

α-Ketohydroxamates were synthesized as bioisosteres of α-ketoamides. The α-ketohydroxamates were generally more potent than the corresponding α-ketoamides. The potency of the compounds suggests that hydrogen bonding and steric bulk of substituents on the nitrogen atom of the ketoamide moiety influence calpain inhibition.

Synthesis of di- and tripeptide analogues containing α-ketoamide as a new core structure for inhibition of HIV-1 protease

Di- and tripeptide analogues containing α-ketoamide as a new core structure and incorporating allophenylnorstatine (Apns) as a transition state mimic, were designed and synthesized in the hope of obtaining a novel structural type of HIV-1 protease inhibitors. The immediate precursor, Apns-Thz-NHBu(t) was prepared by coupling of Boc-Apns with N-tert·butyl Thz-4-carboxamide hydrochloride. Removal of Boc group followed by coupling with the respective α-ketoacid residue (P2) gave the desired dipeptides (8-12) in almost quantitative yields. The α-keto tripeptides (18-21) were obtained by oxidation of the hydroxyl group of Apns (PI) in the appropriate tripeptide, iQOA-Val-Apns-(un)substituted Thz(Oxa)-NHBu1 with DMSO/DCC. Preliminary evaluation of the activity of the synthesized derivatives was determined as percentage of enzyme inhibition at 5 μM and 50 nM levels of the di- and tripeptides respectively. The α-ketoamides displayed a significant enhanced potency relative to their parent isosteres as inhibitors of HIV-1 protease and are shown to be a promising new core structure for the development of enzyme inhibitors. A quantitative approach was attempted, using an LFE model, correlating the effect of structural modification and HIV-1 protease inhibition activity of the prepared dipeptides. The result indicates the contribution of the torsion angle by 84% to the activity of the inhibitors. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

Synthesis and calpain inhibitory activity of α-ketoamides with 2,3-methanoleucine stereoisomers at the P2 position

A series of novel ketoamides incorporating all four 2,3-methanoleucine stereoisomers at the P2 position was synthesized. The compounds displayed a wide variation in K(i) values for inhibition of calpain I depending on the configuration of the P

Process for preparing beta -amino- alpha -hydroxy acid derivatives

PCT No. PCT/JP97/02844 Sec. 371 Date May 14, 1999 Sec. 102(e) Date May 14, 1999 PCT Filed Aug. 18, 1997 PCT Pub. No. WO98/07687 PCT Pub. Date Feb. 26, 1998An object of the present invention is to provide a process for producing a beta -amino- alpha -hydro